Skip to main content
Article thumbnail
Location of Repository

Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs

By Xueli Jia, Kevin Cassar, Graham Mowatt, Jennifer Margaret Burr, Jonathan Alistair Cook and Cynthia Mary Fraser

Abstract

Background: Foam sclerotherapy is a potential treatment for lower limb venous disease. Methods: A systematic review, with no restriction on study design, to assess the safety and efficacy of foam sclerotherapy. Results: 69 studies were included. For serious adverse events including pulmonary embolism and deep vein thrombosis, the median event rates were less than 1%. Median rate for visual disturbance was 1.4%. Median rates for some other adverse events were more common, including headache (4.2%), thrombophlebitis (4.7%), matting/skin staining/pigmentation (17.8%) and pain at the site of injection (25.6%). Median rate for complete occlusion of treated veins was 87.0% and for recurrence or development of new veins was 8.1%. Evidence from meta-analysis for complete occlusion suggests that foam sclerotherapy is associated with a lower rate compared with surgery (RR 0.86, 95% CI 0.67 to 1.10) and a higher rate compared with liquid sclerotherapy (RR 1.39, 95% CI 0.91 to 2.11). However, there was substantial heterogeneity across the studies in the meta-analysis. Conclusion: Serious adverse events were rare. There is insufficient evidence to reliably compare the effectiveness of foam sclerotherapy with other minimally invasive therapies or surgery. Evidence from high quality randomised controlled trials is required.This manuscript is based on a systematic review commissioned and funded by the National Institute for Health and Clinical Excellence (NICE) through its Interventional Procedures Programme. The Health Services Research Unit is supported by a core grant from the Chief Scientist Office of the Scottish Executive Health Department

Topics: Varicose veins, Sclerotherapy, Systematic review
Publisher: Wiley
Year: 2007
OAI identifier: oai:aura.abdn.ac.uk:2164/163
Journal:

Suggested articles

Citations

  1. (2003). Aethoxysclerol foam obliteration of insufficient perforating veins in patients suffering from leg ulcers: a clinical recommentation. UIP World Cognress Chapter Meeting,
  2. Australian and New Zealand doi
  3. (2006). Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg doi
  4. (2005). Clinical and hemodynamic outcomes of duplexguided foam sclerotherapy: a 24 month follow-up study. 15th UIP World Congress,
  5. (2002). Combination therapy for the treatment of recurrent varicose veiins after ligation and stripping using transcatheter sclerotherapy, endovenous laser and phlebectomy.
  6. Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins.
  7. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg doi
  8. (2003). Compression implication of large vein sclerotherapy with sclerosant foam. UIP World Congress, American Chapter Meeting,
  9. (2003). Congress, American Chapter Meeting,
  10. Contributions to the therapy of the varicose complex.
  11. (2005). Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg doi
  12. (2005). Duplex ultrasonography-guided foam sclerotherapy of incompetent perforator veins in a patient with bilateral venous leg ulcers. Dermatol Surg doi
  13. (2001). Duplex-guided sclerotherapy of cavernoma. 14th UIP World Congress,
  14. Echoguided sclerotherapy with 1% trombovar foam via short endovenous catheter (m.s.method): results.
  15. Echosclerosis using sodium tetradecyl-sulphate and polidocanol foam: Two years experience.
  16. Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results. doi
  17. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. doi
  18. (1997). Elargissement des limites de la sclerotherapie: nouveaux produits sclerosants.
  19. (2003). European Consensus Meeting on Foam Sclerotherapy, doi
  20. (2003). Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg doi
  21. (2003). Foam closure of the long saphenous vein: preliminary report.
  22. (2003). Foam echo-sclerotherapy of incompetent saphenous veins. UIP World Congress, American Chapter Meeting,
  23. (2003). Foam echosclerotherapy of incompetent saphenous veins. Phlebolymphology
  24. Foam sclerotherapy of the great saphenous veins via ultrasound-guided catheter in an empty vein: the alpha-technique.
  25. Foam treatment for varicose veins; efficacy and safety.
  26. (2003). French experience with Varisolve PD microfoam in the management of moderate to severe varicose veins. UIP World Congress, American Chapter Meeting,
  27. Garcia-Olmedo MA et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. doi
  28. Garcia-Olmedo MA. Sclerosants in microfoam. A new approach in angiology. doi
  29. (2005). Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg doi
  30. (2005). La sclerotherapi a la moussemau cours de la chirurgie des varices: indications et resultats. Séance de la Societe Francaise de Phlebologi, La sclerotherapie a la mousse en pratique;
  31. (2002). Large volume microfoam therapy for recurrent variscose veins. American College of Phlebology, 16th Annual Congress,
  32. (2003). Long-term follow-up study of ultrasound findings in varicose greater saphenous veins treated with foam. UIP World Congress, American Chapter Meeting,
  33. members of the Executive Committee. Classification and grading of chronic venous disease in the lower limbs: a consensus statement. doi
  34. (2004). Microfoam ultrasound-guided sclerotherapy treatment for varicose veins in a subgroup with diameters at the junction of 10 mm or greater compared with a subgroup of less than 10 mm. Dermatol Surg doi
  35. Mixed skin ulcers misdiagnosed as pyoderma gangrenosum and rheumatoid ulcer: successful treatment with ultrasoundguided injection of polidocanol microfoam. doi
  36. Needle-size and efficacy of foam sclerotherapy.
  37. (2000). Nouvelle technique d'obtention de la sclero-mousse. Phlebologie
  38. (2002). Observations on the use of foamed sodium tetradecyl sulfate for treatment of telangiectasias and reticular veins.
  39. Perforans varicosis: treatment of the incompetent perforating vein is important. Dermatol Surg 2004;30(5):754-755. 31. Weaver PR. Recurrent scintillating scotomata precipitated by sclerotherapy. doi
  40. Polidocanol foam: migraine with aura. Phlebologie 2005;58(3):289-291 73. Kritzinger P. Complications of foam sclerotherapy: three case presentations.
  41. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. doi
  42. Prospective study on foam sclerotherapy.
  43. randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg doi
  44. (2002). Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg doi
  45. Sclerosis of the great saphenous vein: short term results.
  46. Sclerotherapie a la mousee dans les recidives après chirurgie. Séance de la Societe Francaise de Phlebologi, La sclerotherapie a la mousse en pratique;
  47. (2004). Sclerotherapy of the small saphenous vein: how to avoid bad results? Phlebologie
  48. (2001). Sclerotherapy: comparison of techniques. Introductory lecture: state of the art. 14th UIP World Congress,
  49. Short-term results of ultrasound-guided sclerotherapy for venous insufficiency.
  50. Stroke after varicose vein foam injection sclerotherapy. doi
  51. Study 3/j.polidocanol foam 3% versus 1% in the great saphenous vein: early results. doi
  52. surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). doi
  53. (1999). Telangiectases and reticular veins treatment with a 0,25% aetoxisclerol foam presentation of a pilot study.
  54. (1995). The incidence of patent foramen ovale in 1000 consecutive patients. A contrast transesophageal echocardiography study. doi
  55. The role of sclerosing foam in ultrasound guided sclerotherapy of the saphenous veins and of recurrent varicose veins. Australian and New Zealand doi
  56. (1997). Treatement sclerosant des troncs sapheneisetleurs collaterales e gros caliber par la methode MUS.
  57. Treatment of varices greater than 8mm in diameter with foam echosclerotherpy and compression.
  58. Treatment of varicose veins by foam sclerotherapy: Two clinical series. doi
  59. Ultrasound guided foam sclerotherapy (UGFS) early outcome of treatment in 220 limbs.
  60. (2001). ultrasound guided polidocanol foam sclerotherapy: a prospective study of toxicity and complications.
  61. (2006). Ultrasound guided sclerotherapy. Diagnose venous disease and treat superficial venous incompetence with injected sclerosants under ultrasound guidance [document on the Internet]. Australasian College of Phlebology [accessed
  62. Ultrasound-guided foam sclerotherapy combined with sapheno-femoral ligation compared to surgical treatment of varicose veins: early results of a randomised controlled trial. doi
  63. Varisolve® polidocanol microfoam compared with surgery or sclerotherapy in the 18 management of varicose veins in the presence of trunk vein incompetence: European randomised controlled trial.
  64. Venous disorders: treatment with sclerosant foam. doi
  65. ZonMW foam study: Stripping versus duplex guided foam sclerotherapy as treatment far the greater varicose veins. Nederlands Tijdschrift voor Dermatologie &

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.